Modulation of the Apolipoprotein M/S1PR4 Pathway Reduces Podocyte Lipid Overload in Alport Syndrome via Distinct Autophagy and Efflux Mechanisms
Journal of the American Society of Nephrology · 2026
DOI: 10.1681/asn.0000000996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2026. Verfasst von Matthew Tolerico und 14 weiteren Autor:innen. Beteiligte Einrichtung: Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine, Miami, Florida. Hauptthemen laut MEDLINE: Podocytes, Nephritis, Hereditary, Autophagy, Apolipoproteins M. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, US Department of Defense, Miami Clinical and Translational Science Institute, University of Miami.
Abstract (Originalsprache)
Key Points We identified dysregulation of the apolipoprotein M/sphingosine-1-phosphate/sphingosine-1-phosphate receptor 4 (S1PR4) axis in the glomeruli and podocytes of a mouse model of Alport syndrome. Exogenous apolipoprotein M or antagonism of S1PR4 was sufficient to prevent kidney failure, podocyte injury, and lipid accumulation. Apolipoprotein M reduced lipid accumulation in podocytes via cholesterol efflux, while S1PR4 antagonism promoted autophagy of lipid droplets.
Background
Renal lipid dysmetabolism contributes to glomerular disease progression, including Alport syndrome. We recently identified alterations in the apolipoprotein M (APOM)/sphingosine-1-phosphate (S1P)/S1P receptor 4 signaling axis in glomeruli from patients with glomerular disease.
Methods
We used Col4a3 knockout mice and immortalized podocytes derived from these mice as a mouse model of Alport syndrome. Mice and podocytes were treated with recombinant APOM or the S1P receptor 4–specific antagonist, CYM50358.
Results
Col4a3 −/− glomeruli and podocytes exhibited reduced APOM and increased S1P receptor 4 expression and increased sphingosoine-1-phosphate levels, mirroring findings in patients with glomerular disease. Treatment with APOM or CYM50358 reduced albuminuria, BUN, and plasma creatinine and ameliorated glomerulosclerosis, tubulointerstitial fibrosis, podocyte loss, and foot process effacement. Both treatments reduced triglyceride and cholesterol accumulation in glomeruli and podocytes. RNA-seq analysis of Col4a3 −/− revealed that S1P receptor 4 antagonism upregulated lysosomal and autophagy-related genes. Western blot analysis confirmed increased LC3-II/LC3-I ratios and decreased p62, indicating enhanced autophagic flux. Treated podocytes showed increased lysosome numbers and colocalization with lipid droplets. By contrast, APOM had no effect on autophagy but promoted cholesterol efflux. Furthermore, knockdown of APOM or overexpression of sphingosine-1-phosphate receptor 4 was sufficient to cause podocyte cell death.
Conclusions
We found that the APOM/S1P axis was dysregulated in Col4a3 −/− podocytes. Targeting this pathway through APOM supplementation or S1P receptor 4 antagonism improved kidney function and reduced lipid accumulation by enhancing either cholesterol efflux or autophagy, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine, Miami, Florida.
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
- Department of Human Genetics, University of Miami Miller School of Medicine, Miami, Florida.
- Department of Clinical Laboratory Medicine, The University of Tokyo, Tokyo, Japan.
- Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida.
- Centers for Therapeutic Innovation, Pfizer Inc., Cambridge, Massachusetts.
ORCID-Profile: Matthew Tolerico, Arianna Insenga, Anthony Griswold, Makoto Kurano, Armando Mendez, Robin Nathans, Alessia Fornoni, Sandra Merscher
Förderung
- NIDDK NIH HHS
- US Department of Defense
- Miami Clinical and Translational Science Institute, University of Miami
- NCATS NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Pfizer Inc.
Zitieren
APA
Tolerico, M., Molina, J., Insenga, A., Carrazco, A., Njeim, R., Sloan, A., Griswold, A., Kurano, M., Mendez, A., Nathans, R., Bolek, R., Ettou, S., Berasi, S., Fornoni, A., & Merscher, S. (2026). Modulation of the Apolipoprotein M/S1PR4 Pathway Reduces Podocyte Lipid Overload in Alport Syndrome via Distinct Autophagy and Efflux Mechanisms. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000996
Vancouver
Tolerico M, Molina J, Insenga A, Carrazco A, Njeim R, Sloan A, et al. Modulation of the Apolipoprotein M/S1PR4 Pathway Reduces Podocyte Lipid Overload in Alport Syndrome via Distinct Autophagy and Efflux Mechanisms. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000000996
BibTeX
@article{Tolerico2026,
author = {Tolerico, Matthew and Molina, Judith and Insenga, Arianna and Carrazco, Arianna and Njeim, Rachel and Sloan, Alexis and Griswold, Anthony and Kurano, Makoto and Mendez, Armando and Nathans, Robin and Bolek, Robin and Ettou, Sandrine and Berasi, Stephen and Fornoni, Alessia and Merscher, Sandra},
title = {Modulation of the Apolipoprotein M/S1PR4 Pathway Reduces Podocyte Lipid Overload in Alport Syndrome via Distinct Autophagy and Efflux Mechanisms},
journal = {Journal of the American Society of Nephrology},
year = {2026},
doi = {10.1681/asn.0000000996}
}
EUVIMED